Propofol administration in patients with methylmalonic acidemia and intracellular cobalamin metabolism disorders

a review of theoretical concerns and clinical experiences in 28 patients

Yiouli P. Ktena, Trygg Ramstad, Eva H. Baker, Jennifer L. Sloan, Andrew J. Mannes, Irini Manoli, Charles P. Venditti

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Methylmalonic acidemia and intracellular cobalamin metabolism disorders represent a heterogeneous group of inborn errors of metabolism. Most patients will require diagnostic and/or therapeutic procedures frequently requiring sedation or anesthetic management due to neurological and neurocognitive impairments. It has been stated that propofol is contraindicated in this population. We report our experience with propofol administration in a large series of patients. Methods: Twenty eight patients (14 mut, seven cblC, three cblA, three cblB, one cblG) aged 2–35.6 years enrolled in a natural history study (ClinicalTrials.gov identifier: NCT00078078) and required anesthetics for 39 diagnostic or therapeutic procedures. Data were collected on the anesthetic technique, perianesthetic course, and adverse events related to propofol. Results: Propofol was used as the sole induction agent in most cases (36/39) and as the primary maintenance agent in all cases. Infusion rates were 100–400 mcg kg−1 min−1 (mean = 214). Infusion duration was 60–325 min (mean = 158) and total doses ranged between 270–3610 mg (mean = 1217). Adverse events were recorded in two cases; neither appeared to be related to propofol administration. Conclusions: Propofol is an effective, safe induction and maintenance agent for elective short procedures requiring anesthesia in patients with MMA and cobalamin metabolism disorders. Despite multiple comorbidities and propensity toward instability, those affected can receive anesthesia with an acceptable safety profile, if metabolically and hemodynamically stabilized prior to the event. Synopsis: A review of the perianesthetic records of 28 patients with isolated MMA and intracellular cobalamin metabolism disorders suggests that propofol anesthesia can be administered safely to these patients, in the setting of metabolic stability.

Original languageEnglish (US)
Pages (from-to)847-853
Number of pages7
JournalJournal of Inherited Metabolic Disease
Volume38
Issue number5
DOIs
StatePublished - Oct 1 2015
Externally publishedYes

Fingerprint

Propofol
Vitamin B 12
Anesthetics
Anesthesia
Maintenance
Inborn Errors Metabolism
Methylmalonic acidemia
Natural History
Comorbidity
Safety
Therapeutics
Population

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Propofol administration in patients with methylmalonic acidemia and intracellular cobalamin metabolism disorders : a review of theoretical concerns and clinical experiences in 28 patients. / Ktena, Yiouli P.; Ramstad, Trygg; Baker, Eva H.; Sloan, Jennifer L.; Mannes, Andrew J.; Manoli, Irini; Venditti, Charles P.

In: Journal of Inherited Metabolic Disease, Vol. 38, No. 5, 01.10.2015, p. 847-853.

Research output: Contribution to journalArticle

Ktena, Yiouli P. ; Ramstad, Trygg ; Baker, Eva H. ; Sloan, Jennifer L. ; Mannes, Andrew J. ; Manoli, Irini ; Venditti, Charles P. / Propofol administration in patients with methylmalonic acidemia and intracellular cobalamin metabolism disorders : a review of theoretical concerns and clinical experiences in 28 patients. In: Journal of Inherited Metabolic Disease. 2015 ; Vol. 38, No. 5. pp. 847-853.
@article{12c3e3d4e88d4319ba601bc75c5866e8,
title = "Propofol administration in patients with methylmalonic acidemia and intracellular cobalamin metabolism disorders: a review of theoretical concerns and clinical experiences in 28 patients",
abstract = "Background: Methylmalonic acidemia and intracellular cobalamin metabolism disorders represent a heterogeneous group of inborn errors of metabolism. Most patients will require diagnostic and/or therapeutic procedures frequently requiring sedation or anesthetic management due to neurological and neurocognitive impairments. It has been stated that propofol is contraindicated in this population. We report our experience with propofol administration in a large series of patients. Methods: Twenty eight patients (14 mut, seven cblC, three cblA, three cblB, one cblG) aged 2–35.6 years enrolled in a natural history study (ClinicalTrials.gov identifier: NCT00078078) and required anesthetics for 39 diagnostic or therapeutic procedures. Data were collected on the anesthetic technique, perianesthetic course, and adverse events related to propofol. Results: Propofol was used as the sole induction agent in most cases (36/39) and as the primary maintenance agent in all cases. Infusion rates were 100–400 mcg kg−1 min−1 (mean = 214). Infusion duration was 60–325 min (mean = 158) and total doses ranged between 270–3610 mg (mean = 1217). Adverse events were recorded in two cases; neither appeared to be related to propofol administration. Conclusions: Propofol is an effective, safe induction and maintenance agent for elective short procedures requiring anesthesia in patients with MMA and cobalamin metabolism disorders. Despite multiple comorbidities and propensity toward instability, those affected can receive anesthesia with an acceptable safety profile, if metabolically and hemodynamically stabilized prior to the event. Synopsis: A review of the perianesthetic records of 28 patients with isolated MMA and intracellular cobalamin metabolism disorders suggests that propofol anesthesia can be administered safely to these patients, in the setting of metabolic stability.",
author = "Ktena, {Yiouli P.} and Trygg Ramstad and Baker, {Eva H.} and Sloan, {Jennifer L.} and Mannes, {Andrew J.} and Irini Manoli and Venditti, {Charles P.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1007/s10545-015-9816-x",
language = "English (US)",
volume = "38",
pages = "847--853",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Netherlands",
number = "5",

}

TY - JOUR

T1 - Propofol administration in patients with methylmalonic acidemia and intracellular cobalamin metabolism disorders

T2 - a review of theoretical concerns and clinical experiences in 28 patients

AU - Ktena, Yiouli P.

AU - Ramstad, Trygg

AU - Baker, Eva H.

AU - Sloan, Jennifer L.

AU - Mannes, Andrew J.

AU - Manoli, Irini

AU - Venditti, Charles P.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background: Methylmalonic acidemia and intracellular cobalamin metabolism disorders represent a heterogeneous group of inborn errors of metabolism. Most patients will require diagnostic and/or therapeutic procedures frequently requiring sedation or anesthetic management due to neurological and neurocognitive impairments. It has been stated that propofol is contraindicated in this population. We report our experience with propofol administration in a large series of patients. Methods: Twenty eight patients (14 mut, seven cblC, three cblA, three cblB, one cblG) aged 2–35.6 years enrolled in a natural history study (ClinicalTrials.gov identifier: NCT00078078) and required anesthetics for 39 diagnostic or therapeutic procedures. Data were collected on the anesthetic technique, perianesthetic course, and adverse events related to propofol. Results: Propofol was used as the sole induction agent in most cases (36/39) and as the primary maintenance agent in all cases. Infusion rates were 100–400 mcg kg−1 min−1 (mean = 214). Infusion duration was 60–325 min (mean = 158) and total doses ranged between 270–3610 mg (mean = 1217). Adverse events were recorded in two cases; neither appeared to be related to propofol administration. Conclusions: Propofol is an effective, safe induction and maintenance agent for elective short procedures requiring anesthesia in patients with MMA and cobalamin metabolism disorders. Despite multiple comorbidities and propensity toward instability, those affected can receive anesthesia with an acceptable safety profile, if metabolically and hemodynamically stabilized prior to the event. Synopsis: A review of the perianesthetic records of 28 patients with isolated MMA and intracellular cobalamin metabolism disorders suggests that propofol anesthesia can be administered safely to these patients, in the setting of metabolic stability.

AB - Background: Methylmalonic acidemia and intracellular cobalamin metabolism disorders represent a heterogeneous group of inborn errors of metabolism. Most patients will require diagnostic and/or therapeutic procedures frequently requiring sedation or anesthetic management due to neurological and neurocognitive impairments. It has been stated that propofol is contraindicated in this population. We report our experience with propofol administration in a large series of patients. Methods: Twenty eight patients (14 mut, seven cblC, three cblA, three cblB, one cblG) aged 2–35.6 years enrolled in a natural history study (ClinicalTrials.gov identifier: NCT00078078) and required anesthetics for 39 diagnostic or therapeutic procedures. Data were collected on the anesthetic technique, perianesthetic course, and adverse events related to propofol. Results: Propofol was used as the sole induction agent in most cases (36/39) and as the primary maintenance agent in all cases. Infusion rates were 100–400 mcg kg−1 min−1 (mean = 214). Infusion duration was 60–325 min (mean = 158) and total doses ranged between 270–3610 mg (mean = 1217). Adverse events were recorded in two cases; neither appeared to be related to propofol administration. Conclusions: Propofol is an effective, safe induction and maintenance agent for elective short procedures requiring anesthesia in patients with MMA and cobalamin metabolism disorders. Despite multiple comorbidities and propensity toward instability, those affected can receive anesthesia with an acceptable safety profile, if metabolically and hemodynamically stabilized prior to the event. Synopsis: A review of the perianesthetic records of 28 patients with isolated MMA and intracellular cobalamin metabolism disorders suggests that propofol anesthesia can be administered safely to these patients, in the setting of metabolic stability.

UR - http://www.scopus.com/inward/record.url?scp=84940462048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940462048&partnerID=8YFLogxK

U2 - 10.1007/s10545-015-9816-x

DO - 10.1007/s10545-015-9816-x

M3 - Article

VL - 38

SP - 847

EP - 853

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

IS - 5

ER -